Determination of higenamine in multi-matrix by gas chromatography-mass spectrometry combined with derivatization technology

Higenamine (HG), a cardioactive component of some foods and medicines, has been listed in the doping category by the International Olympic Committee, which may lead to misuse by athletes. We report the development of a gas chromatography-mass spectrometry (GC–MS) method for determination of HG in various matrix samples (biological samples, different forms of Chinese patent medicine, Chinese herbal medicine) based on acylation derivatization of HG by heptafluorobutyric anhydride. Under optimal conditions, the linearity of HG in the range of 5–200 ng mL⁻¹ was acceptable (R² > 0.999), and the limit of detection (LOD) and limit of quantitation (LOQ) for HG was 1.52 ng mL⁻¹ and 5 ng mL⁻¹, respectively. Low, medium, and high concentrations (25, 100 and 160 ng mL⁻¹) of HG were added to plasma, urine, oral liquid, capsule, watered bolus, honeyed bolus and Chinese herbal medicine samples, with recovery ranging from 82.70 to 109.80%, intra-day and inter-day precisions were both less than 3.39%. The results indicated that the method had sufficient sensitivity for analysis of biological samples, and Chinese patent and herbal medicine.     

大气细颗粒物对心血管系统的影响及营养干预研究进展

目的 总结大气细颗粒物对心血管系统的影响及营养物质保护作用的研究进展。方法 通过用“大气细颗粒物”、“心血管”、“维生素”、“脂肪酸”、“矿物质”、“植物化学物”等关键词对CNKI、PUBMED数据库进行文献检索,了解大气细颗粒物对心血管系统的影响及营养物质对心血管系统保护作用的实验研究结果。结果 大气细颗粒物通过氧化应激、炎症反应诱发心血管系统损伤。维生素、矿物质、脂肪酸和植物化学物等营养素发挥着重要的保护作用。 结论 大气细颗粒物在造成心血管损伤的过程中,某些营养物质可以起到一定的保护作用。     

环状RNA在动脉粥样硬化中的研究进展

环状RNA(circRNA)是一类新型内源性非编码RNA,广泛存在于真核生物体中,因其含量丰富、序列保守、结构稳定等特性,是近年来热门的基因表达调节因子。越来越多的研究表明circRNA在影响内皮完整性、血管平滑肌细胞和免疫炎症细胞的功能,以及在驱动动脉粥样硬化(As)斑块起始和稳定中发挥重要作用,因此其可能作为As新型诊断生物标志物和治疗靶标。因此,文章就circRNA在As中研究现状,综述其在As中的功能以及调节机制。     

Determination of 12 anti-obesity drugs in human plasma by a 96-well protein precipitation plate using HPLC-MS

An analytical method was developed and validated for the simultaneous determination of 12 anti-obesity drugs (methylephedrine (MER), amphetamine (AMP), fenfluramine (FEN), bupropion (BUP), fluoxetine (FLU), sibutramine (SIBU), bisacodyl (BISA), bumetanide (BUM), lovastatin (LOVA), simvastatin (SIM), rimonabant (RIMO), and fenofibrate (FENO)) in human plasma by a 96-well protein precipitation plate combined with high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). The 96-well protein precipitation plate was chosen for simultaneous pretreatment of large sample volumes, making the whole process more efficient and faster. Drugs were separated on an Agilent Poroshell 120 EC-C18 column, and detected by MS/MS under multiple reaction monitoring (MRM) mode. The developed method was validated in terms of linearity, matrix effect, accuracy and precision. A good linearity was obtained in the range of 0.1–20.0 ng mL⁻¹ for fenfluramine, bupropion, fluoxetine, sibutramine, bisacodyl, and rimonabant; and 0.5–20.0 ng mL⁻¹ for methylephedrine, amphetamine, bumetanide, lovastatin, simvastatin, and fenofibrate with a correlation coefficient above 0.995. The method was fully validated with an acceptable accuracy of 75.63–108.21%, matrix effect of 80.41–117.71% except for fenofibrate (76.07% at low concentration levels), and precision of 0.32–13.12%. Owing to the advantages of simple operation, high accuracy and sensitivity, this method is suitable for the rapid and simultaneous detection of 12 anti-obesity drugs in human plasma, providing support for clinically monitoring the development of adverse reactions and guiding the rational and appropriate use of weight-loss drugs for obese people.

A 96-well protein precipitation plate combined with HPLC-MS/MS was developed for the determination of 12 anti-obesity drugs in human plasma; the detection method showed high throughout and high sensitivity with suitable recovery.